Hanbang Technology submitted its IPO registration to the Shanghai Stock Exchange, focusing on chromatography separation and purification products.

On February 24th, Jiangsu Hanbang Technology Co., Ltd. (referred to as Hanbang Technology) applied for the change of IPO review status on the Shanghai Stock Exchange's Science and Technology Innovation Board to "submitted for registration." CITIC SEC is its sponsoring institution, aiming to raise 5.98 billion yuan. The prospectus disclosed that Hanbang Technology is a high-tech enterprise with chromatography technology as its core, integrating research and development, production, and sales. It is committed to "refined chromatography technology, dedicated to human health," striving to become the leading brand in the international chromatography industry. It mainly provides professional separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical, life sciences, and other fields. Through continuous research and development, Hanbang Technology has overcome technical challenges in chromatographic linear amplification and purification, achieving linear amplification of separation and purification from gram-level, ten-gram-level, hundred-gram-level to kilogram-level. Its products and technology are widely used in the research and production of drugs and natural products such as antibodies, recombinant proteins, vaccines, insulin, peptides, contrast agents, antibiotics, breaking the long-term monopoly of foreign technology and products. It has become a leading enterprise in the research, production, and industrialization of chromatography separation and purification equipment in China, effectively promoting domestic substitution of chromatography separation and purification equipment and the industrial upgrading of downstream pharmaceutical industry. The company's main products can be divided into small molecule drug separation and purification equipment, large molecule drug separation and purification equipment, etc., which can be widely used in various application scenarios in industrial production and laboratory research. During the reporting period, with a comprehensive product layout and leading customer service capabilities, the company timely responded to downstream market demand for various equipment products and actively explored overseas markets. From 2021 to 2023, the compound annual growth rate of the company's main business revenue reached 38.99%, maintaining a growth trend. After deducting the corresponding issuance expenses from the funds raised in this public offering of shares, Hanbang Technology will invest in the following projects: Financially, in the fiscal year 2021, 2022, 2023, and January to June 2024, Hanbang Technology achieved operating income of approximately 321 million yuan, 482 million yuan, 619 million yuan, and 329 million yuan respectively. During the same period, the company achieved net profits of approximately 4.8617 million yuan, 38.5596 million yuan, 51.4975 million yuan, and 37.6849 million yuan respectively.